Citi analyst Joanne Wuensch lowered the firm’s price target on Becton Dickinson to $255 from $260 and keeps a Neutral rating on the shares as part of a Q2 earnings preview for the U.S. medical technology space. While Citi anticipates that investors will “continue to lean into quality names that have consistently beat and raised,” with the significant reset in valuations across the group there is “opportunity across the cap stack,” the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDX:
- Becton Dickinson added to ‘Tactical Outperform’ list, target trimmed at Evercore
- 3 Best Healthcare Stocks to Buy in June 2024, as per Analysts
- M&A News: BDX Snaps Up Edwards Life’s Critical Care Unit in $4.2B Deal
- Becton Dickinson’s $4.2B Acquisition of Edwards Lifesciences Group
- Becton Dickinson to acquire critical care product group from Edwards for $4.2B